A study to evaluate the effect of a licensed drug to lower blood glucose, liraglutide, on inflammation in patients with diabetic kidney disease.

Registry ID

EUCTR2012-005482-12

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

University College Dublin

Start date

2013-03-08

Completion date

2015-10-08

Last update

2026-08-16

Conditions

• Diabetic Kidney Disease

Summary

Primary Objective: The primary objective of this study is to compare the change in pro-inflammatory cytokine monocyte-chemotactic protein 1 (MCP-1) in urine in subjects treated with liraglutide over a 26 week treatment period versus a matched control group who received no liraglutide.

Locations

• , , Ireland

Related clinical trials

• Real World Evidence Clinical Utility Study of KidneyIntelX
• Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
• The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.
• Mechanism of SGLT2 Inhibition in the Kidney
• Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
• Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease

View on source registry